Whittier Trust Co. Purchases 339 Shares of The Cooper Companies, Inc. $COO

Whittier Trust Co. boosted its position in The Cooper Companies, Inc. (NASDAQ:COO) by 5.1% during the 2nd quarter, Holdings Channel.com reports. The fund owned 6,952 shares of the medical device company’s stock after buying an additional 339 shares during the quarter. Whittier Trust Co.’s holdings in Cooper Companies were worth $495,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new position in Cooper Companies during the first quarter worth about $33,000. J.Safra Asset Management Corp boosted its holdings in Cooper Companies by 204.8% during the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after buying an additional 340 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in Cooper Companies during the first quarter worth about $40,000. Larson Financial Group LLC boosted its holdings in Cooper Companies by 1,071.0% during the first quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock worth $61,000 after buying an additional 664 shares during the last quarter. Finally, HM Payson & Co. boosted its holdings in Cooper Companies by 147.4% during the first quarter. HM Payson & Co. now owns 893 shares of the medical device company’s stock worth $75,000 after buying an additional 532 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Insiders Place Their Bets

In other news, COO Gerard H. Warner III bought 1,450 shares of the company’s stock in a transaction that occurred on Friday, September 5th. The shares were acquired at an average price of $69.23 per share, with a total value of $100,383.50. Following the transaction, the chief operating officer owned 18,319 shares in the company, valued at $1,268,224.37. This represents a 8.60% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel G. Mcbride bought 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was purchased at an average cost of $65.04 per share, for a total transaction of $195,120.00. Following the transaction, the chief operating officer owned 63,120 shares in the company, valued at $4,105,324.80. The trade was a 4.99% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 17,975 shares of company stock worth $1,216,346 in the last 90 days. Company insiders own 1.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Mizuho reduced their target price on Cooper Companies from $105.00 to $90.00 and set an “outperform” rating on the stock in a report on Wednesday, July 16th. Stifel Nicolaus reduced their target price on Cooper Companies from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, August 28th. Robert W. Baird reduced their target price on Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, August 28th. BNP Paribas Exane upgraded Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Tuesday, July 22nd. Finally, Wells Fargo & Company dropped their price target on Cooper Companies from $93.00 to $72.00 and set an “overweight” rating on the stock in a research report on Thursday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Cooper Companies presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.77.

Cooper Companies Trading Up 0.1%

NASDAQ COO opened at $74.52 on Friday. The firm has a market cap of $14.82 billion, a P/E ratio of 36.71, a P/E/G ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. The stock’s 50-day moving average is $69.67 and its 200-day moving average is $73.22. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $109.04.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the firm posted $0.96 earnings per share. Cooper Companies’s revenue was up 5.7% compared to the same quarter last year. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies announced that its Board of Directors has initiated a share buyback plan on Wednesday, September 17th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical device company to buy up to 15.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.